Clavis Pharma™ develops new and superior pharmaceuticals by leveraging the potential of its Lipid Vector Technology (LVT). The Company’s objective is to build an attractive pipeline of new drug candidates in oncology and subsequently license these out to strategic partners for further co-development and marketing. Revenues will be generated already at the time of partnering and onwards from up-front payments milestone payments and royalties from licensees.



